Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Specialty Sites
    • COVID-19
    • Practice Current
    • Practice Buzz
    • Without Borders
    • Equity, Diversity and Inclusion
    • Innovations in Care Delivery
  • Collections
    • Topics A-Z
    • Residents & Fellows
    • Infographics
    • Patient Pages
    • Null Hypothesis
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Residents & Fellows

Share

April 09, 2019; 92 (15 Supplement) May 10, 2019

Results of the Dose-Escalation Portion of a Phase 2 Study of ACE-083, a Local Muscle Therapeutic, in Patients with Charcot-Marie-Tooth (CMT) Disease (S58.006)

Florian P. Thomas, Michael Shy, David Herrmann, Jeffrey Statland, David Walk, Colin Quinn, Nicholas Johnson, SH Subramony, Chafic Karam, Tahseen Mozaffar, Chad E. Glasser, Barry Miller, Ashley Leneus, Robert K. Zeldin, Kenneth M. Attie
First published April 16, 2019,
Florian P. Thomas
1Hackensack UMC and Hackensack Meridian School of Medicine Hackensack NJ United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Shy
2University of Iowa Iowa City IA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Herrmann
3University of Rochester Medical Center Rochester NY United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey Statland
4University of Kansas Medical Center Kansas City KS United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Walk
5Dept. of Neurology, University of Minnesota Minneapolis MN United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Colin Quinn
6University of Pennsylvania Philadelphia PA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas Johnson
7University of Utah Salt Lake City UT United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SH Subramony
8University of Florida Gainesville FL United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chafic Karam
9Oregon Health & Science University Portland OR United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tahseen Mozaffar
10University of California Irvine Orange CA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chad E. Glasser
11Acceleron Pharma Cambridge MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barry Miller
11Acceleron Pharma Cambridge MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ashley Leneus
11Acceleron Pharma Cambridge MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert K. Zeldin
11Acceleron Pharma Cambridge MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth M. Attie
11Acceleron Pharma Cambridge MA United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Citation
Results of the Dose-Escalation Portion of a Phase 2 Study of ACE-083, a Local Muscle Therapeutic, in Patients with Charcot-Marie-Tooth (CMT) Disease (S58.006)
Florian P. Thomas, Michael Shy, David Herrmann, Jeffrey Statland, David Walk, Colin Quinn, Nicholas Johnson, SH Subramony, Chafic Karam, Tahseen Mozaffar, Chad E. Glasser, Barry Miller, Ashley Leneus, Robert K. Zeldin, Kenneth M. Attie
Neurology Apr 2019, 92 (15 Supplement) S58.006;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
0

Share

  • Article
  • Info & Disclosures
Loading

Abstract

Objective: To evaluate the effects of ACE-083 injected into the tibialis anterior (TA) muscle of patients with CMT1 or CMTX and mild-moderate ankle dorsiflexion weakness.

Background: ACE-083 is a locally-acting protein therapeutic consisting of a modified form of human follistatin that binds myostatin plus other negative regulators of muscle. ACE-083 has been shown to increase muscle mass and force in neuromuscular disease mouse models and to increase muscle mass in healthy volunteers and patients with facioscapulohumeral dystrophy (FSHD).

Design/Methods: This ongoing, multicenter study evaluates safety and tolerability (Part 1); pharmacokinetics, pharmacodynamics, and efficacy (Part 2), of ACE-083 administered bilaterally into the TA every 3 weeks. Part 1 is 3-month, open-label with 3 dose cohorts (150, 200, 240 mg/muscle, n=6 each); Part 2 is 6-month, placebo-controlled, followed by 6-month open-label (n=40 planned).

Results: As of 24 Aug 2018, preliminary Part 1 data are: median (range) age 48 yrs (18–62); 11 patients with CMT1A, 4 with CMT1B, and 3 with CMTX1; median (range) baseline fat fraction (FF) 30% (9–45). No serious AEs were reported and related AEs were primarily injection-site related. Changes in MRI parameters across the 3 cohorts are provided at Day 106 (3 weeks after last dose, average left and right sides). Mean percent increase in total muscle volume was 12.6 to 14.2% and contractile muscle volume increased 15.8 to 19.6%. Mean absolute decrease in FF% was −1.7 to −3.5%.

Conclusions: Local muscle injections of ACE-083 were well tolerated in patients with CMT and resulted in increases in muscle volume and decreases in fat fraction. The ongoing, placebo-controlled Part 2 of the study will evaluate effects on function and quality of life.

Disclosure: Dr. Thomas has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acorda Therapeutics, Biogen, Genzyme, Novartis and Teva Neuroscience. Dr. Thomas has received research support from Biogen and Teva Neuroscience. Dr. Shy has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acceleron. Dr. Herrmann has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Guidepoint Global, GLG. Dr. Herrmann has received royalty, license fees, or contractual rights payments from University of Rochester. Dr. Herrmann has received research support from Acceleron Pharma, Flex Pharma. Dr. Statland has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acceleron Pharma, Inc., Expansion Therapeutics, , Fulcrum Therapeutics, Genea Biocells, and Strongbridge Biopharma. Dr. Statland has received research support from FSH Society, Muscular Dystrophy Association, and the National Institutes of Health. Dr. Walk has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acceleron Pharma. Dr. Walk has received personal compensation in an editorial capacity for Pain Medicine. Dr. Walk has received research support from Acceleron Pharma and PharNEXT. Dr. Quinn has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acceleron Pharma. Dr. Johnson has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acceleron. Dr. Johnson has received personal compensation in an editorial capacity for Continuum. Dr. Johnson has received research support from Acceleron. Dr. Subramony has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acceleron Pharma. Dr. Subramony has received research support from Acceleron, Reata, Takeda, Horizon, and Biohaven. Dr. Karam has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Akcea, Alexion, Alnyalm, Biogen, CSL Behring, Cytokinetics, Genzyme, Guidepoint, GLG. Dr. Karam has received research support from Genzyme. Dr. Mozaffar has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Amicus, Alexion, CSL and Genzyme. Dr. Mozaffar has received research support from Alexion, Amicus, aTyr, Genzyme, Grifols, Idera, Ionis Pharmaceuticals, and Ultragenyx. Dr. Glasser has nothing to disclose. Dr. Miller has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acceleron Pharma. Dr. Leneus has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acceleron Pharma. Dr. Zeldin has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acceleron Pharma, Ablynx. Dr. Attie has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Versartis, Acceleron Pharma.

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
  • Info & Disclosures
Advertisement

Related Articles

  • No related articles found.

Alert Me

  • Alert me when eletters are published
Neurology: 96 (15)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2021 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise